RESILIENT: LifeStent superior to PTA-only strategy


Results of the RESILIENT study were recently presented at the British Society of Interventional Radiology (BSIR) meeting and showed that primary stenting with the LifeStent (Bard) was superior to a PTA-alone strategy in claudicants with SFA/proximal popliteal lesions ≤150mm, at two years.
Two-hundred and six patients (claudicants) were enrolled at 24 sites and primary patency was achieved in 80% of patients in the stent group vs. 38% in the PTA group, and freedom from target lesion revascularisation (TLR) was 87% in the stent group vs. 46% in the PTA group.